Duality Advisers’s Apellis Pharmaceuticals APLS Stock Holding History

Duality Advisers’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11,823	Closed	-$611K	–	548
2022 Q4	$611K	Sell	11,823 -26,234	-69%	-$1.39M	0.07%	405
2022 Q3	$2.6M	Buy	+38,057	New	+$2.25M	0.28%	135
2021 Q4	–	Sell	-111,100	Closed	-$3.66M	–	488
2021 Q3	$3.66M	Buy	+111,100	New	+$6.24M	0.28%	139
2021 Q2	–	Sell	-15,188	Closed	-$652K	–	525
2021 Q1	$652K	Buy	+15,188	New	+$719K	0.06%	412
2020 Q4	–	Sell	-8,800	Closed	-$265K	–	546
2020 Q3	$265K	Buy	+8,800	New	+$263K	0.02%	537

Other funds holding APLS

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Duality Advisers's APLS Position: Q1 2023 in Review

Duality Advisers sold out of Apellis Pharmaceuticals (APLS) in Q1 2023, closing a stake of 11,823 shares — an estimated $611K sold.

Duality Advisers first reported a position in APLS in Q3 2020 and held it in 5 quarters. The position peaked at $3.66M in Q3 2021. 281 funds tracked by Wall St. Rank hold APLS as of Q1 2023.

Duality Advisers reported no remaining Apellis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Duality Advisers sold 11,823 Apellis Pharmaceuticals shares in Q1 2023, an estimated $611K.
Duality Advisers first reported a position in Apellis Pharmaceuticals in Q3 2020 and held it in 5 quarters.
Duality Advisers's Apellis Pharmaceuticals position peaked at $3.66M in Q3 2021.
281 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2023.

Based on Duality Advisers's 13F filing for Q1 2023, filed 27 Jun 2023.